Fig. 2From: Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitorScatterplots of voxelwise association between TBF and [18F]FLT V T for the tumour VOI for one patient at the three different time points: baseline (a), 7 days post-therapy (b) and 28 days post-therapy (c)Back to article page